Pilot and Feasibility Grants h1 >
MGNet, a NIH-funded Rare Diseases Clinical Research Consortium (RDCRC) in partnership with the Myasthenia Gravis Foundation of America and Conquer MG, is seeking proposals for highly innovative investigations in early stages of development. The priorities of the Pilot Grant Program are:
- Identification treatment responsive biomarkers (please see Focus On Biomarkers Research)
- Assess clinical measures and improve that enhance clinical trial readiness
- Evaluation of therapeutic interventions for one or more of the five distinct sub-types of MG (additional information in the full proposal will be required for clinical trials).
Pilot studies must be designed to access the resources of MGNet and focused on clinical research, including fulfilling the definition of clinical research and exclusion of animal studies.
Two years of funding for the pilot project will be $75,000/year (IDCs will be limited to 10% and included in the $75,000), with a start date of June 2023. Selection among the applications received will be based on the recommendations of a review committee.
The PI must hold an MD, PhD, MD/PhD, RN or more advanced, PharmD, DDS, DVM, or equivalent and be a faculty member at an academic institution.
A full proposal submission will consist of
- Specific aims (one page)
- Research plan (four pages)
- NIH bio-sketch for key personnel
- NIH PHS 398 Detailed Budget Page and budget justification with any proposed cost sharing commitment.
- Human subjects and other institutional assurances to perform the intended research including a specific verification of investigator protected time to perform the study.
- Status of an IRB application (applicants are encouraged to initiate an IRB for the proposed work).
Proposals will need to be electronically submitted and the Administrative Core personnel will assure all requirements for submission are fulfilled. Proposals will then undergo peer review by an NIH-style study section assembled by the MGNet. Standard review criteria for the parent announcement NIH R01 will be applied (PA-19-056, or if the application includes a clinical trial PA-19-055).